Which children with idiopathic short stature should receive growth hormone therapy?

  title={Which children with idiopathic short stature should receive growth hormone therapy?},
  author={P. Czernichow},
  journal={Nature Clinical Practice Endocrinology \&Metabolism},
  • P. Czernichow
  • Published 1 March 2008
  • Medicine
  • Nature Clinical Practice Endocrinology &Metabolism
The use of growth hormone to treat children with idiopathic short stature remains an area of controversy. The author of this Viewpoint discusses the possible etiology of idiopathic short stature, the efficacy and safety of the treatment regimen, and which children with this condition should be selected for therapy. 
2 Citations
Performance enhancing endocrinology: the arbitrary line of acceptability.
Endocrinologists now need to consider the legitimate and non-legitimate uses of the medications they prescribe for patients, and discuss these maters openly with their patients, their parents, and with each other.
Surface plasmon resonance biosensor for direct detection of antibodies against human growth hormone.
It was demonstrated that the developed SPR-chip could be stored for at least 21 days before use without considerable loss of sensitivity towards anti-HGH, and the SPR biosensor response for repeatable detections of anti- HGH was highly reproducible and very stable.


Growth hormone treatment of idiopathic short stature.
In general, GH treatment should only be considered in young ISS patients with poor initial PAH and height prognosis, and GH treatment of older patients who have a normal PAH is not justified.
Effect of growth hormone treatment on adult height of children with idiopathic short stature. Genentech Collaborative Group.
Long-term administration of growth hormone to children with idiopathic short stature can increase adult height to a level above the predicted adult height and above the adult height of untreated historical control children.
Efficacy and safety results of long-term growth hormone treatment of idiopathic short stature.
ISS patients in the GH registry demonstrate a significant increase in HtSDS with the safety profile similar to GH-deficient patients, and no new safety signals specific to the NCGS ISS population were observed.
Effect of growth hormone treatment on adult height in peripubertal children with idiopathic short stature: a randomized, double-blind, placebo-controlled trial.
GH treatment increases adult height in peripubertal children with marked idiopathic short stature in a randomized, double-blind, placebo-controlled trial.
Psychological adaptation in children with idiopathic short stature treated with growth hormone or placebo.
GH treatment was associated with a trend toward improvement in problem behaviors, as measured by questionnaires completed by study participants' parents, and it remains to be determined whether GH treatment significantly impacts adaptation, psychosocial function, or quality of life in children with ISS.
Deletions of the homeobox gene SHOX (short stature homeobox) are an important cause of growth failure in children with short stature.
The prevalence of short stature due to SHOX gene mutations among children with short stature appears to be similar to that of GH deficiency or Turner syndrome.
Unique Deletion in Exon 5 of SHOX Gene in a Patient with Idiopathic Short Stature
This case resulted in the description of a novel mutation in exon 5 (M202delA) and suggests the importance of screening for SHOX mutations in patients with idiopathic short stature with subtle radiographic abnormalities, including the components of the Madelung deformity in their bone age films.
Age at Growth Hormone Therapy Start and First-Year Responsiveness to Growth Hormone Are Major Determinants of Height Outcome in Idiopathic Short Stature
Prepubertal children with ISS who show an appropriate first-year response to GH are likely to benefit from long-term treatment, even on low GH dosages, and the model explains 39% of the variability.
Risk factors for diabetes mellitus type 2 and metabolic syndrome are comparable for previously growth hormone-treated young adults born small for gestational age (sga) and untreated short SGA controls.
At 6.5 yr after discontinuation of long-term GH treatment, Si, DI, fasting levels of glucose and insulin, body mass index, waist circumference, and IGF-I and IGFBP-3 levels were equivalent for GH-treated and untreated young SGA adults.